Sage Capital Advisors,Llc Biogen Inc. Transaction History

Sage Capital Advisors,Llc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Jan 16, 2020	SELL	$220.06 - $304.07 $1.49 Million - $2.06 Million	-6,779 Closed	0 $0
Q3 2019 Oct 17, 2019	BUY	$217.44 - $243.88 $23,700 - $26,582	109 Added 1.63%	6,779 $1.58 Million
Q2 2019 Jul 31, 2019	BUY	$219.29 - $241.72 $1.24 Million - $1.36 Million	5,647 Added 552.0%	6,670 $1.55 Million
Q4 2018 Feb 11, 2019	BUY	$278.5 - $352.75 $281,563 - $356,630	1,011 Added 8425.0%	1,023 $308,000
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $3,522 - $4,605	12 New	12 $4,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Sage Capital Advisors,Llc, based on Form 13F filings with the SEC.

Stay updated on Sage Capital Advisors,Llc with notifications on news.